These results also underscore the limitations of relying solely on proliferation and TP53 status for tumor stratification and support the utility of incorporating cell cycle regulators such as cyclin D1 into biomarker panels for improved prognostic or predictive accuracy. This evidence concerns the gene TP53 and neoplasm.